TeneoTwo, Lightspeed, Arch & The Distillery: a BioCentury podcast
AZ’s takeout of a single-asset spinout for $100M up front is but the latest payout to shareholders in TeneoBio
By Jeff Cranmer, Executive Editor
July 6, 2022 2:35 AM UTC
BioCentury
AZ’s takeout of single-asset spinout TeneoTwo for $100 million up front is but the latest payout to shareholders in TeneoBio, who could stand to see even more upside in the years ahead, said Associate Editor Paul Bonanos on the latest edition of the BioCentury This Week podcast.
The deal brings the total sale price of TeneoBio Inc. and associated assets to $1.4 billion thus far, across three upfront payments, and adds a clinical bispecific T cell engager to the pipeline of AstraZeneca plc (LSE:AZN; NASDAQ:AZN). TeneoTwo Inc. spun out from TeneoBio in 2021.
Bonanos and the BioCentury editors also discuss how TeneoTwo Inc. investor Lightspeed Venture Partners has deepened its commitment to life sciences investing, building a portfolio and a dedicated team in the sector; Arch Venture Partners’ plans to deploy its new $3 billion venture fund; and the latest translational highlights from BioCentury’s Distillery and Translational in Brief sections.
To kick off the episode, the podcast team is joined by Josh Berlin, head of BD at BioCentury, who previews this fall’s BioCentury-BayHelix East-West Summit 2022, a gathering of biopharma executives and investors focused on building trusted cross-border relationships across the biopharma ecosystem. The VIP event, which takes place in the San Francisco Bay Area Nov. 14-16 with digital access offered globally, incorporates the ninth BioCentury-BayHelix China Healthcare Summit.
For information on how to sponsor BioCentury This Week and The BioCentury Show, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.
